This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linsley, P. S. Articles by Horn, D. Search for Related Content PubMed PubMed Citation Articles by Linsley, P. S. Articles by Horn, D.

Monoclonal Antibodies Reactive with Mucin Glycoproteins Found in Sera from Breast Cancer Patients

Oncogen, Seattle, Washington 98121 [P. S. L., J. P. B., D. H.] and Laboratory of Structural Biology, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892 [J. L. M.]

Monoclonal antibodies to mucin glycoproteins have previously been shown to detect elevated antigen levels in sera from breast cancer patients. To determine whether different mucin epitopes represent better targets for serum assays, we have produced and characterized 14 new monoclonal antibodies directed against the mucin glycoproteins detected by antibody W1. Many of the new antibodies differed from each other in their ability to bind to mucins from various sources. Cross-competition analyses of antibody binding indicated that while epitopes for some antibodies were distinct, most epitopes showed complex structural or steric relationships with those for other antibodies. Antibody M26 bound glycolipids from meconium and kidney, indicating that it recognized a carbohydrate epitope. Antibodies M15, M22, M23, and M27 bound to structurally or sterically related epitopes on deglycosylated milk-derived mucin, suggesting that they recognized core protein epitopes. Enzyme immunoassays were developed with the new antibodies and evaluated for their ability to discriminate between sera from breast cancer patients and from controls with benign breast disease. The best single test in terms of sensitivity and specificity used a combination of two antibodies, antibody M29 for antigen capture and antibody M38 for antigen detection. A second test using antibody M26 for antigen capture and antibody M38 for antigen detection detected elevated antigen levels in sera from some patients which were in the control range of the M29/M38 test. By combining results from these tests, signifacantly more cancer patients were detected than with the W1 and CA 15.3 tests.

¹ To whom requests for reprints should be addressed, at Oncogen, 3005 First Avenue, Seattle, WA 98121.

Received 8/14/87. Revised 11/30/87. Accepted 1/12/88.

This article has been cited by other articles:

				A. Evangelou, M. Letarte, I. Jurisica, M. Sultan, K. J. Murphy, B. Rosen, and T. J. Brown Loss of Coordinated Androgen Regulation in Nonmalignant Ovarian Epithelial Cells with BRCA1/2 Mutations and Ovarian Cancer Cells Cancer Res., May 15, 2003; 63(10): 2416 - 2424. [Abstract] [Full Text] [PDF]

				A. Evangelou, M. Letarte, A. Marks, and T. J. Brown Androgen Modulation of Adhesion and Antiadhesion Molecules in PC-3 Prostate Cancer Cells Expressing Androgen Receptor Endocrinology, October 1, 2002; 143(10): 3897 - 3904. [Abstract] [Full Text] [PDF]

				E.C. LaCasse, M.R. Bray, B. Patterson, W.-M. Lim, S. Perampalam, L. G. Radvanyi, A. Keating, A.K. Stewart, R. Buckstein, J.S. Sandhu, et al. Shiga-Like Toxin-1 Receptor on Human Breast Cancer, Lymphoma, and Myeloma and Absence From CD34+ Hematopoietic Stem Cells: Implications for Ex Vivo Tumor Purging and Autologous Stem Cell Transplantation Blood, October 15, 1999; 94(8): 2901 - 2910. [Abstract] [Full Text] [PDF]

				A. Baruch, M.-l. Hartmann, M. Yoeli, Y. Adereth, S. Greenstein, Y. Stadler, Y. Skornik, J. Zaretsky, N. I. Smorodinsky, I. Keydar, et al. The Breast Cancer-associated MUC1 Gene Generates Both a Receptor and Its Cognate Binding Protein Cancer Res., April 1, 1999; 59(7): 1552 - 1561. [Abstract] [Full Text] [PDF]